Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical-stage medical device innovator advancing the Hemopurifier® - a therapeutic filtration device targeting cancer-enabling exosomes and life-threatening viruses. This page provides investors and medical professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.
Key resources include press releases detailing trial protocols, ethics committee approvals, and operational milestones. Users will find verified information on oncology applications for treatment-resistant cancers and infectious disease programs, all presented in compliance with financial disclosure standards.
Content highlights encompass FDA communications, trial enrollment updates, and peer-reviewed research collaborations. The curated news collection serves as a reliable reference for tracking the Hemopurifier®'s progress through clinical validation stages and potential therapeutic applications.
Bookmark this page for direct access to Aethlon Medical's official announcements, including breakthrough device designations and international trial expansions. Check regularly for updates on this pioneering approach to blood filtration technology and its implications for cancer immunotherapy advancement.
Aethlon Medical (AEMD) announced a peer-reviewed article published in PLOS ONE, showcasing that its GNA affinity resin in the Hemopurifier effectively captures seven SARS-CoV-2 variants, with efficacy ranging from 53% to 89%. CEO Charles J. Fisher emphasized the potential of the Hemopurifier in addressing emerging COVID-19 variants. The company is currently conducting an Early Feasibility Study involving 40 severe COVID-19 patients, and recently received FDA protocol amendment approval to eliminate prior dialysis treatment, which may expedite patient enrollment.
Aethlon Medical (AEMD) announced FDA approval for a protocol amendment in its ongoing clinical trial for the Aethlon Hemopurifier® targeting severe COVID-19 patients. The amendment removes the requirement for patients to have a dialysis catheter, potentially accelerating patient enrollment. The Hemopurifier is designed to filter out life-threatening viruses and harmful exosomes from blood and is being evaluated in a feasibility study involving up to 40 patients across multiple clinical sites. The company aims to enhance patient access to this innovative therapy.
Aethlon Medical (Nasdaq: AEMD) reported financials for the fiscal year ended March 31, 2022, revealing a cash balance of $17.1 million and a revenue of approximately $294,000, a decline from $659,000 in the prior year. Operating expenses rose to $10.72 million from $8.55 million, leading to a net loss of $10.4 million. The company is advancing the Hemopurifier for COVID-19 treatment and cancer, enrolling patients across multiple sites. Recent developments include ethics approval for a clinical trial in India and the appointment of Angela Rossetti to the Board.
Aethlon Medical, Inc. (Nasdaq: AEMD) will announce its financial results for the fiscal year ending March 31, 2022, on June 28, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss these results and recent corporate developments. The Hemopurifier, Aethlon's lead technology, is designed to treat cancer and infectious diseases, holding FDA Breakthrough Device designation for advanced cancer therapy and addressing life-threatening viruses. A replay of the conference will be available for a month post-call.
Aethlon Medical, Inc. (AEMD), a medical technology company, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami Beach, Florida, and virtually. The presentation, led by CEO Charles J. Fisher, Jr., CMO Steven LaRosa, and CFO James Frakes, will cover updates on the Hemopurifier®, a device aimed at treating cancer and viral infections. The presentation will be available on-demand starting May 24, 2022, at 7 a.m. EDT. The Hemopurifier® has received FDA designations as a Breakthrough Device for cancer and life-threatening viral infections, including COVID-19.
Aethlon Medical announced the publication of a pre-print manuscript showing its GNA affinity resin can capture seven SARS-CoV-2 variants, including Delta and Omicron, with efficiency rates between 53% and 89%. This resin is part of the Aethlon Hemopurifier®, an investigational device designed to remove viruses from the blood. The company is conducting an Early Feasibility Study on the Hemopurifier for COVID-19 patients. This research supports the potential effectiveness of the Hemopurifier against future variants, as stated by CEO Charles J. Fisher, Jr.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced the appointment of Angela Rossetti to its Board of Directors, effective April 1, 2022. She replaces Sabrina Martucci Johnson, who steps down to focus on other roles. Rossetti brings over 20 years of biopharmaceutical experience, having held significant positions at various companies, including Pfizer. Her expertise in medical and clinical affairs is expected to boost the company's clinical advancements, particularly for the Hemopurifier, a device aimed at treating infectious diseases and cancer.
Aethlon Medical, Inc. (Nasdaq: AEMD) reported its financial results for the third quarter ending December 31, 2021. The company had a cash balance of approximately $20.4 million but recorded only $17,000 in revenue, a significant drop from $625,000 in the same period last year. Operating expenses decreased to $2.55 million, resulting in a net loss of about $2.5 million. Aethlon is advancing the Hemopurifier™ in clinical trials for Severe COVID and cancer, with progress made in patient enrollment across multiple sites.
Aethlon Medical, Inc. (Nasdaq: AEMD) will announce its financial results for Q3 FY2022, concluding on December 31, 2021, on February 14, 2022, at 4:15 p.m. EST. Management will hold a conference call at 4:30 p.m. EST to discuss these results and recent developments, followed by a Q&A session. The Hemopurifier, Aethlon's lead technology, is a FDA-designated Breakthrough Device aimed at treating advanced cancer and life-threatening infectious diseases. It has shown promising results in human studies, particularly in removing harmful viruses and exosomes from blood.
